Pembrolizumab 加 Epacadostat、Pembrolizumab 单一疗法,以及治疗复发性或转移性头颈鳞状细胞癌的极端方案 (KEYNOTE-669/ECHO-304)
一项评估 Pembrolizumab 加 Epacadostat、Pembrolizumab 单一疗法和 EXTREME 方案作为一线治疗复发性或转移性头颈部鳞状细胞癌的疗效和安全性的 3 期随机、开放标签临床研究 (KEYNOTE-669/ECHO-304 )
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
研究概览
地位
地位
干预/治疗
干预/治疗
研究类型
研究类型
注册 (实际的)
注册
阶段
阶段
- 第三阶段
联系人和位置
学习地点
-
-
Ontario
-
Hamilton、Ontario、加拿大、L8V 5C2
- Juravinski Cancer Center Hamilton Health Sciences
-
Toronto、Ontario、加拿大、M5G 2M9
- Princess Margaret Cancer Centre
-
-
Quebec
-
Montreal、Quebec、加拿大、H3T 1E2
- Jewish General Hospital
-
Québec、Quebec、加拿大、G1R 3S1
- CHU de Quebec-Universite Laval-Hotel Dieu de Quebec
-
-
-
-
-
Miskolc、匈牙利、3526
- Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz
-
Szolnok、匈牙利、5000
- Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet
-
-
-
-
-
Tainan、台湾、70457
- National Cheng Kung University Hospital
-
Taipei、台湾、10048
- National Taiwan University Hospital
-
Taoyuan、台湾、33305
- Chang Gung Medical Foundation. Linkou
-
-
-
-
-
Adana、土耳其(türkiye)、01370
- Adana Sehir Hastanesi
-
Ankara、土耳其(türkiye)、06100
- Hacettepe Universitesi Tip Fakultesi Hastanesi
-
Edirne、土耳其(türkiye)、22030
- Trakya Universitesi Tip Fakultesi
-
Istanbul、土耳其(türkiye)、34093
- Istanbul Universitesi Onkoloji Enstitusu
-
Istanbul、土耳其(türkiye)、34214
- Medipol Hastanesi
-
Izmir、土耳其(türkiye)、35040
- Ege Universitesi Tip Fakultesi Hastanesi
-
Malatya、土耳其(türkiye)、44280
- Inonu Universitesi Turgut Ozal Tip Merkezi
-
-
-
-
-
Salzburg、奥地利、5020
- Landeskrankenhaus Salzburg
-
Vienna、奥地利、1090
- Allgemeines Krankenhaus der Stadt Wien
-
-
-
-
-
Milan、意大利、20141
- Istituto Europeo di Oncologia
-
Rozzano、意大利、20089
- IRRCS Instituto Clinico Humanitas
-
-
-
-
-
Akashi、日本、673-8558
- Hyogo Cancer Center
-
Fukuoka、日本、812-8582
- Kyushu University Hospital
-
Hiroshima、日本、734-8551
- Hiroshima University Hospital
-
Hokkaido、日本、060-8648
- Hokkaido University Hospital
-
Kobe、日本、650-0047
- Kobe City Medical Center General Hospital
-
Saitama、日本、362-0806
- Saitama Cancer Center
-
Sayama、日本、589-8511
- Kindai University Hospital
-
Shizuoka、日本、411-8777
- Shizuoka Cancer Center Hospital and Research Institute
-
Tokyo、日本、135-8550
- The Cancer Institute Hospital of JFCR
-
-
Chiba
-
Kashiwa、Chiba、日本、277-8577
- National Cancer Center Hospital East
-
-
Ishikawa-ken
-
Kanazawa、Ishikawa-ken、日本、920-8641
- Kanazawa University Hospital
-
-
Kanagawa
-
Yokohama、Kanagawa、日本、241-8515
- Kanagawa Cancer Center
-
-
Miyagi
-
Natori-shi、Miyagi、日本、981-1293
- Miyagi Cancer Center
-
Sendai、Miyagi、日本、980-8574
- Tohoku University Hospital
-
-
-
-
-
Konin、波兰、62-500
- Przychodnia Lekarska Komed
-
Szczecin、波兰、71-730
- Zachodniopomorskie Centrum Onkologii
-
-
Masovian Voivodeship
-
Wieliszew、Masovian Voivodeship、波兰、05-135
- Mazowiecki Szpital Onkologiczny
-
-
-
-
New South Wales
-
Camperdown、New South Wales、澳大利亚、2050
- Chris OBrien Lifehouse
-
North Ryde、New South Wales、澳大利亚、2109
- Macquarie University Hospital
-
-
Queensland
-
Herston、Queensland、澳大利亚、4029
- Royal Brisbane & Women s Hospital
-
-
-
-
California
-
Anaheim、California、美国、19026
- Pacific Cancer Medical Center
-
Sacramento、California、美国、95817
- UC Davis Comprehensive Cancer Center
-
Santa Rosa、California、美国、95403
- St. Joseph Heritage Healthcare
-
-
Colorado
-
Aurora、Colorado、美国、80045
- University of Colorado Cancer Center
-
-
Connecticut
-
New Haven、Connecticut、美国、06520
- Yale Cancer Center
-
-
Georgia
-
Douglasville、Georgia、美国、30134
- Northwest Georgia Oncology Centers PC
-
-
Kansas
-
Westwood、Kansas、美国、66205
- U of Kansas Cancer Center
-
-
Kentucky
-
Louisville、Kentucky、美国、40223
- Baptist Health
-
-
Montana
-
Billings、Montana、美国、59102
- St. Vincent Healthcare Cancer Ctr
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87106
- New Mexico Cancer Care Alliance
-
-
Oklahoma
-
Tulsa、Oklahoma、美国、74146
- Oklahoma Cancer Specialists and Research
-
-
Oregon
-
Portland、Oregon、美国、97213
- Providence Portland Med Center
-
-
Utah
-
Salt Lake City、Utah、美国、19026
- Huntsman Cancer Institute Univ of Utah
-
-
Washington
-
Seattle、Washington、美国、98101
- Viginia Mason Med Ctr
-
-
-
-
-
London、英国、N18 1QX
- North Middlesex Hospital
-
London、英国、NW1 2PG
- University College London Hospitals (UCLH)
-
London、英国、SW3 6JJ
- The Royal Marsden Foundation Trust
-
London、英国、SW3 6JJ
- The Royal Marsden Nhs Foundation Trust - Chelsea
-
Taunton、英国、TA1 5DA
- Musgrove Park Hospital
-
-
-
-
-
Coimbra、葡萄牙、3000-075
- Inst. Portugues de Oncologia de Coimbra Frencisco Gentil EPE
-
Lisbon、葡萄牙、1099-023
- Inst. Portugues de Oncologia de Lisboa Francisco Gentil EPE
-
Lisbon、葡萄牙、1649-035
- Centro Hospitalar Lisboa Norte EPE - Hospital de Santa Maria
-
Porto、葡萄牙、4200-072
- Inst. Portugues de Oncologia de Porto Francisco Gentil EPE
-
-
-
-
-
Badalona、西班牙、08916
- Hospital Germans Trias i Pujol. ICO de Badalona
-
Barcelona、西班牙、08035
- Hospital General Universitari Vall d Hebron
-
Madrid、西班牙、28041
- Hospital Universitario 12 de Octubre
-
Madrid、西班牙、28034
- Hospital Ramon y Cajal
-
Madrid、西班牙、28981
- Hospital Infanta Cristina
-
Seville、西班牙、41014
- Hospital de Nuestra Senora de Valme
-
Zaragoza、西班牙、50009
- Hospital Clinico Lozano Blesa
-
-
-
-
-
Seoul、韩国、03080
- Seoul National University Hospital
-
Seoul、韩国、05505
- Asan Medical Center
-
Seoul、韩国、03722
- Severance Hospital Yonsei University Health System
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Measurable disease based on RECIST v1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ function per protocol-defined criteria.
- Documentation of results from testing of human papilloma virus (HPV) status for oropharyngeal cancer.
- Baseline archival tumor specimen available or willing to undergo a prestudy treatment tumor core or excisional biopsy of a tumor lesion not previously irradiated, to obtain the specimen.
Exclusion Criteria:
- Carcinoma of the nasopharynx, salivary gland, unknown primary origin, or nonsquamous histologies as primary tumors.
- Disease progression within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.
- Use of protocol-defined prior/concomitant therapy.
- Known additional malignancy that is progressing or has required active treatment within the past 3 years.
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Active autoimmune disease that has required systemic treatment in past 2 years.
- Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.
- Known history of or is positive for active hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (defined as HCV RNA [qualitative] is detected).
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:派姆单抗
|
Pembrolizumab administered intravenously every 3 weeks.
其他名称:
|
|
实验性的:派姆单抗 + 依帕卡司他
|
Pembrolizumab administered intravenously every 3 weeks.
其他名称:
Epacadostat administered orally twice daily.
其他名称:
|
|
有源比较器:EXTREME
EXTREME regimen includes cetuximab + cisplatin or carboplatin + 5-fluorouracil. |
Cetuximab administered intravenously on Cycle 1 Day 1 followed by administration every week. Cisplatin administered intravenously every 3 weeks for </= 6 cycles. Carboplatin administered intravenously every 3 weeks for </= 6 cycles. 5-Fluorouracil administered intravenously every 3 weeks for </= 6 cycles. |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective Response Rate (ORR) of Pembrolizumab + Epacadostat, Pembrolizumab Monotherapy and the EXTREME Regimen
大体时间:Minimum Week 9
|
ORR was defined as the percentage of participants who had a complete response (CR), disappearance of all target lesions or partial response (PR), >=30% decrease in the sum of the longest diameter of target lesions per RECIST v1.1 by investigator determination. Responses are based on investigator assessments per RECIST 1.1 without confirmation using all available scans. |
Minimum Week 9
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety and Tolerability of Pembrolizumab + Epacadostat Versus Pembrolizumab Versus the EXTREME Regimen as Measured by Number of Participants Experiencing Adverse Events (AEs)
大体时间:up to approximately 8 years
|
AE is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. |
up to approximately 8 years
|
|
Safety and Tolerability of Pembrolizumab + Epacadostat Versus Pembrolizumab Versus the EXTREME Regimen as Measured by Number of Participants Discontinuing Study Treatment Due to AEs
大体时间:up to approximately 8 years
|
AE is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. |
up to approximately 8 years
|
合作者和调查者
调查人员
调查人员
- 研究主任:Mark Jones, MD、Incyte Corporation
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (实际的)
初级完成
研究完成 (实际的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
其他研究编号
- KEYNOTE-669/ECHO 304
- 2017 (美国 NIH 拨款/合同)
- 2017-001338-24 (EudraCT编号)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.